 Benjamin Frank
Concepts (281)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 17 | 2025 | 1925 | 3.270 |
Why?
| | Heart Defects, Congenital | 14 | 2025 | 851 | 1.850 |
Why?
| | Ventricular Dysfunction, Left | 6 | 2022 | 365 | 1.670 |
Why?
| | Pulmonary Artery | 10 | 2025 | 1109 | 1.320 |
Why?
| | Hernias, Diaphragmatic, Congenital | 2 | 2023 | 201 | 1.300 |
Why?
| | Fontan Procedure | 5 | 2024 | 182 | 1.200 |
Why?
| | Endothelin-1 | 2 | 2022 | 177 | 1.190 |
Why?
| | Echocardiography | 7 | 2025 | 638 | 1.070 |
Why?
| | Ventricular Dysfunction, Right | 4 | 2023 | 239 | 1.040 |
Why?
| | Kynurenine | 3 | 2024 | 115 | 1.030 |
Why?
| | Cardiopulmonary Bypass | 8 | 2025 | 217 | 1.010 |
Why?
| | Tryptophan | 3 | 2024 | 183 | 0.990 |
Why?
| | Cardiac Catheterization | 5 | 2025 | 528 | 0.970 |
Why?
| | Infant | 23 | 2025 | 9586 | 0.900 |
Why?
| | Hemodynamics | 11 | 2025 | 1093 | 0.900 |
Why?
| | Cardiac Surgical Procedures | 6 | 2024 | 576 | 0.890 |
Why?
| | Acetamides | 1 | 2024 | 36 | 0.860 |
Why?
| | Matrix Metalloproteinase 8 | 1 | 2023 | 8 | 0.830 |
Why?
| | Citrulline | 1 | 2024 | 45 | 0.830 |
Why?
| | Nitric Oxide | 3 | 2024 | 893 | 0.820 |
Why?
| | Pyrazines | 1 | 2024 | 87 | 0.820 |
Why?
| | Heart Ventricles | 9 | 2024 | 745 | 0.800 |
Why?
| | Arginine | 1 | 2024 | 261 | 0.770 |
Why?
| | Blood Proteins | 2 | 2020 | 244 | 0.760 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2024 | 335 | 0.760 |
Why?
| | Aortic Coarctation | 2 | 2023 | 79 | 0.750 |
Why?
| | Heart Bypass, Right | 1 | 2022 | 17 | 0.740 |
Why?
| | Infant, Premature, Diseases | 2 | 2023 | 105 | 0.730 |
Why?
| | Ventricular Function, Left | 4 | 2023 | 502 | 0.680 |
Why?
| | Child | 29 | 2025 | 21946 | 0.660 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2020 | 67 | 0.660 |
Why?
| | Heart Diseases | 1 | 2023 | 336 | 0.650 |
Why?
| | Heart Function Tests | 1 | 2019 | 56 | 0.630 |
Why?
| | Infant, Newborn | 15 | 2025 | 6159 | 0.610 |
Why?
| | Scurvy | 1 | 2019 | 17 | 0.590 |
Why?
| | Prospective Studies | 11 | 2024 | 7666 | 0.590 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2019 | 25 | 0.590 |
Why?
| | Atrial Function, Right | 3 | 2025 | 13 | 0.580 |
Why?
| | Biomarkers | 8 | 2024 | 4095 | 0.570 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2019 | 119 | 0.560 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 2023 | 387 | 0.560 |
Why?
| | Diagnostic Imaging | 1 | 2020 | 320 | 0.550 |
Why?
| | Humans | 58 | 2025 | 139072 | 0.540 |
Why?
| | Pediatrics | 2 | 2024 | 1079 | 0.520 |
Why?
| | Ventricular Remodeling | 1 | 2019 | 257 | 0.510 |
Why?
| | Magnetic Resonance Imaging, Cine | 4 | 2025 | 197 | 0.460 |
Why?
| | Retrospective Studies | 15 | 2025 | 15919 | 0.440 |
Why?
| | Treatment Outcome | 11 | 2025 | 10930 | 0.440 |
Why?
| | Pain | 1 | 2019 | 779 | 0.400 |
Why?
| | Familial Primary Pulmonary Hypertension | 4 | 2022 | 198 | 0.400 |
Why?
| | Computed Tomography Angiography | 2 | 2025 | 131 | 0.400 |
Why?
| | Adolescent | 16 | 2025 | 21594 | 0.390 |
Why?
| | Matrix Metalloproteinase 7 | 2 | 2023 | 25 | 0.370 |
Why?
| | Male | 28 | 2025 | 68299 | 0.360 |
Why?
| | Hypoplastic Left Heart Syndrome | 2 | 2025 | 117 | 0.360 |
Why?
| | Ventricular Function, Right | 3 | 2023 | 279 | 0.350 |
Why?
| | Predictive Value of Tests | 7 | 2025 | 2032 | 0.340 |
Why?
| | Heart Failure | 1 | 2024 | 2065 | 0.340 |
Why?
| | Pulmonary Veins | 2 | 2023 | 106 | 0.340 |
Why?
| | Hypoxia | 3 | 2024 | 1150 | 0.340 |
Why?
| | Vasodilator Agents | 2 | 2025 | 329 | 0.330 |
Why?
| | Myocardial Contraction | 3 | 2020 | 303 | 0.330 |
Why?
| | Antihypertensive Agents | 3 | 2024 | 505 | 0.320 |
Why?
| | Female | 27 | 2025 | 74071 | 0.320 |
Why?
| | Case-Control Studies | 5 | 2025 | 3577 | 0.310 |
Why?
| | Microfilament Proteins | 4 | 2003 | 132 | 0.300 |
Why?
| | Pulmonary Valve | 1 | 2010 | 91 | 0.300 |
Why?
| | Length of Stay | 4 | 2025 | 1238 | 0.300 |
Why?
| | Postoperative Complications | 5 | 2021 | 2721 | 0.290 |
Why?
| | Child, Preschool | 11 | 2025 | 11171 | 0.280 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 2 | 2025 | 26 | 0.270 |
Why?
| | Arterial Pressure | 2 | 2025 | 131 | 0.260 |
Why?
| | Palliative Care | 3 | 2025 | 815 | 0.260 |
Why?
| | Tissue Engineering | 1 | 2010 | 426 | 0.250 |
Why?
| | Vascular Stiffness | 2 | 2021 | 443 | 0.250 |
Why?
| | Stroke Volume | 3 | 2025 | 584 | 0.240 |
Why?
| | Morbidity | 2 | 2024 | 321 | 0.240 |
Why?
| | Carrier Proteins | 4 | 2003 | 738 | 0.240 |
Why?
| | Prognosis | 3 | 2025 | 3999 | 0.230 |
Why?
| | Proteomics | 2 | 2023 | 1112 | 0.230 |
Why?
| | Hemorrhage | 2 | 2021 | 747 | 0.230 |
Why?
| | Magnetic Resonance Imaging | 7 | 2024 | 3640 | 0.230 |
Why?
| | SOXF Transcription Factors | 1 | 2024 | 16 | 0.220 |
Why?
| | Kynurenic Acid | 1 | 2024 | 20 | 0.220 |
Why?
| | Serotonin | 2 | 2024 | 322 | 0.220 |
Why?
| | Norwood Procedures | 1 | 2025 | 29 | 0.220 |
Why?
| | Multidetector Computed Tomography | 1 | 2025 | 40 | 0.220 |
Why?
| | Graft Occlusion, Vascular | 1 | 2025 | 39 | 0.220 |
Why?
| | Echocardiography, Doppler | 1 | 2025 | 112 | 0.210 |
Why?
| | Acute Kidney Injury | 2 | 2022 | 812 | 0.210 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2023 | 28 | 0.210 |
Why?
| | History, 21st Century | 1 | 2024 | 214 | 0.200 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2023 | 40 | 0.200 |
Why?
| | Vascular Resistance | 1 | 2024 | 364 | 0.200 |
Why?
| | Models, Cardiovascular | 2 | 2024 | 197 | 0.200 |
Why?
| | Stenosis, Pulmonary Vein | 1 | 2023 | 19 | 0.200 |
Why?
| | History, 20th Century | 1 | 2024 | 324 | 0.200 |
Why?
| | Infant, Extremely Premature | 1 | 2023 | 66 | 0.190 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2022 | 41 | 0.190 |
Why?
| | Atrioventricular Block | 1 | 2022 | 37 | 0.190 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 157 | 0.190 |
Why?
| | Phenylpropionates | 1 | 2022 | 21 | 0.180 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 115 | 0.180 |
Why?
| | Fetal Diseases | 1 | 2023 | 177 | 0.180 |
Why?
| | Pyridazines | 1 | 2022 | 56 | 0.180 |
Why?
| | Amino Acids | 1 | 2025 | 497 | 0.180 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2021 | 19 | 0.180 |
Why?
| | Risk Factors | 5 | 2025 | 10390 | 0.180 |
Why?
| | Phosphoproteins | 1 | 2003 | 340 | 0.180 |
Why?
| | Protein Conformation | 2 | 2003 | 946 | 0.180 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 275 | 0.170 |
Why?
| | Ventricular Function | 1 | 2021 | 57 | 0.170 |
Why?
| | Administration, Inhalation | 2 | 2021 | 595 | 0.170 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2003 | 613 | 0.170 |
Why?
| | Postoperative Period | 1 | 2022 | 355 | 0.170 |
Why?
| | Matrix Metalloproteinases | 1 | 2021 | 95 | 0.170 |
Why?
| | Pulmonary Atresia | 1 | 2020 | 21 | 0.160 |
Why?
| | Preoperative Period | 1 | 2020 | 142 | 0.160 |
Why?
| | Heart Atria | 1 | 2021 | 137 | 0.160 |
Why?
| | Proteome | 1 | 2024 | 471 | 0.160 |
Why?
| | Metabolomics | 3 | 2021 | 689 | 0.160 |
Why?
| | Societies, Medical | 1 | 2024 | 838 | 0.160 |
Why?
| | Electrophysiological Phenomena | 1 | 2019 | 58 | 0.160 |
Why?
| | Aortic Valve Stenosis | 1 | 2022 | 242 | 0.160 |
Why?
| | Extracellular Matrix | 1 | 2023 | 541 | 0.150 |
Why?
| | Lung | 3 | 2023 | 4107 | 0.150 |
Why?
| | Gingiva | 1 | 2019 | 25 | 0.150 |
Why?
| | Mechanical Phenomena | 1 | 2019 | 85 | 0.150 |
Why?
| | Regional Blood Flow | 1 | 2021 | 496 | 0.150 |
Why?
| | Coronary Care Units | 1 | 2018 | 21 | 0.150 |
Why?
| | Cholecalciferol | 1 | 2019 | 60 | 0.150 |
Why?
| | Infant, Premature | 2 | 2023 | 580 | 0.150 |
Why?
| | Pulmonary Alveoli | 1 | 2021 | 408 | 0.140 |
Why?
| | Transcriptome | 1 | 2025 | 969 | 0.140 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2018 | 260 | 0.140 |
Why?
| | Alkaline Phosphatase | 1 | 2019 | 149 | 0.140 |
Why?
| | Chest Pain | 1 | 2019 | 96 | 0.140 |
Why?
| | Endotoxemia | 1 | 2019 | 87 | 0.140 |
Why?
| | Endotoxins | 1 | 2019 | 220 | 0.140 |
Why?
| | Biomedical Research | 1 | 2024 | 696 | 0.140 |
Why?
| | Ascorbic Acid | 1 | 2019 | 179 | 0.130 |
Why?
| | Leg | 1 | 2019 | 233 | 0.130 |
Why?
| | Heart Transplantation | 1 | 2023 | 708 | 0.130 |
Why?
| | Cohort Studies | 2 | 2024 | 5749 | 0.130 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2021 | 751 | 0.130 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 591 | 0.130 |
Why?
| | Iron | 1 | 2019 | 324 | 0.130 |
Why?
| | Risk | 1 | 2019 | 913 | 0.120 |
Why?
| | Swine | 3 | 2025 | 801 | 0.120 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 1997 | 105 | 0.120 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 556 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1281 | 0.120 |
Why?
| | Actins | 3 | 2003 | 419 | 0.120 |
Why?
| | Down Syndrome | 1 | 2021 | 483 | 0.110 |
Why?
| | Lung Diseases | 1 | 2021 | 785 | 0.110 |
Why?
| | Intubation, Intratracheal | 1 | 1997 | 279 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2019 | 559 | 0.110 |
Why?
| | Stents | 2 | 2025 | 526 | 0.110 |
Why?
| | Time Factors | 3 | 2021 | 6869 | 0.110 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 1045 | 0.100 |
Why?
| | Blood Pressure | 1 | 2019 | 1739 | 0.100 |
Why?
| | Amino Acid Sequence | 4 | 2003 | 2160 | 0.090 |
Why?
| | Wounds and Injuries | 1 | 2019 | 834 | 0.090 |
Why?
| | Molecular Sequence Data | 4 | 2003 | 2926 | 0.090 |
Why?
| | Diastole | 2 | 2022 | 141 | 0.080 |
Why?
| | Purines | 2 | 2022 | 179 | 0.080 |
Why?
| | Drainage | 1 | 2011 | 173 | 0.080 |
Why?
| | Cell Count | 1 | 2010 | 325 | 0.080 |
Why?
| | Bile Duct Neoplasms | 1 | 2011 | 115 | 0.080 |
Why?
| | Adult | 3 | 2023 | 38428 | 0.080 |
Why?
| | Anastomosis, Surgical | 2 | 2021 | 158 | 0.080 |
Why?
| | Cholestasis | 1 | 2011 | 208 | 0.070 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 2 | 2002 | 344 | 0.070 |
Why?
| | Metabolome | 2 | 2021 | 352 | 0.070 |
Why?
| | Peptide Fragments | 2 | 2003 | 694 | 0.070 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3315 | 0.070 |
Why?
| | Keratan Sulfate | 1 | 2006 | 1 | 0.060 |
Why?
| | Histidine | 2 | 2003 | 65 | 0.060 |
Why?
| | Synovial Fluid | 1 | 2006 | 72 | 0.060 |
Why?
| | Protein Folding | 3 | 2002 | 276 | 0.060 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2006 | 139 | 0.060 |
Why?
| | Circular Dichroism | 2 | 2002 | 150 | 0.060 |
Why?
| | Age Factors | 2 | 2025 | 3276 | 0.060 |
Why?
| | Organ Specificity | 1 | 2025 | 310 | 0.050 |
Why?
| | Language Development | 1 | 2024 | 61 | 0.050 |
Why?
| | Hyaluronic Acid | 1 | 2006 | 226 | 0.050 |
Why?
| | Vena Cava, Inferior | 1 | 2024 | 73 | 0.050 |
Why?
| | Syndrome | 1 | 2024 | 377 | 0.050 |
Why?
| | Erythrocyte Membrane | 1 | 2003 | 53 | 0.050 |
Why?
| | Osteoarthritis | 1 | 2006 | 200 | 0.050 |
Why?
| | Models, Molecular | 3 | 2003 | 1599 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2020 | 3705 | 0.050 |
Why?
| | Serine | 1 | 2003 | 141 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2482 | 0.050 |
Why?
| | Binding Sites | 2 | 2003 | 1317 | 0.050 |
Why?
| | Protein Structure, Tertiary | 2 | 2002 | 862 | 0.050 |
Why?
| | Molecular Structure | 1 | 2003 | 502 | 0.050 |
Why?
| | Pulmonary Circulation | 1 | 2024 | 438 | 0.050 |
Why?
| | Tadalafil | 1 | 2022 | 7 | 0.050 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2002 | 86 | 0.050 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2022 | 36 | 0.050 |
Why?
| | Phenylalanine | 1 | 2002 | 68 | 0.050 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2021 | 16 | 0.040 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2002 | 188 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2002 | 376 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2002 | 310 | 0.040 |
Why?
| | Niacinamide | 1 | 2021 | 82 | 0.040 |
Why?
| | Methionine | 1 | 2021 | 159 | 0.040 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2020 | 34 | 0.040 |
Why?
| | Patient-Specific Modeling | 1 | 2020 | 42 | 0.040 |
Why?
| | Gestational Age | 1 | 2023 | 918 | 0.040 |
Why?
| | Survival Rate | 2 | 2011 | 1936 | 0.040 |
Why?
| | Systole | 1 | 2020 | 174 | 0.040 |
Why?
| | Computer Simulation | 1 | 2024 | 996 | 0.040 |
Why?
| | Coronary Circulation | 1 | 2020 | 136 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 193 | 0.040 |
Why?
| | Aortic Valve | 1 | 2022 | 355 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2002 | 663 | 0.040 |
Why?
| | Phosphorylation | 1 | 2003 | 1767 | 0.040 |
Why?
| | Time | 1 | 2019 | 88 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2022 | 1032 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 611 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2020 | 449 | 0.040 |
Why?
| | Animals | 5 | 2025 | 37261 | 0.040 |
Why?
| | Myocardium | 1 | 2023 | 921 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1766 | 0.030 |
Why?
| | Aorta | 1 | 2020 | 416 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1748 | 0.030 |
Why?
| | Electrophysiologic Techniques, Cardiac | 1 | 2018 | 75 | 0.030 |
Why?
| | Escherichia coli | 1 | 2002 | 827 | 0.030 |
Why?
| | Nevada | 1 | 1997 | 8 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2025 | 2853 | 0.030 |
Why?
| | United States | 2 | 2025 | 15078 | 0.030 |
Why?
| | Poisson Distribution | 1 | 1997 | 77 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1165 | 0.030 |
Why?
| | Blood Flow Velocity | 1 | 2018 | 411 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2020 | 739 | 0.030 |
Why?
| | Confidence Intervals | 1 | 1997 | 335 | 0.030 |
Why?
| | Liver | 1 | 2025 | 1807 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1570 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 1997 | 262 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2018 | 564 | 0.030 |
Why?
| | Kidney | 1 | 2022 | 1467 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2018 | 920 | 0.030 |
Why?
| | Oxygen | 1 | 2018 | 977 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 2697 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2021 | 5153 | 0.020 |
Why?
| | Retreatment | 1 | 2011 | 73 | 0.020 |
Why?
| | Chickens | 2 | 2002 | 189 | 0.020 |
Why?
| | Catheterization | 1 | 2011 | 182 | 0.020 |
Why?
| | Radiography, Interventional | 1 | 2011 | 119 | 0.020 |
Why?
| | Incidence | 1 | 1997 | 2832 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3466 | 0.020 |
Why?
| | Bone Morphogenetic Protein 7 | 1 | 2006 | 12 | 0.020 |
Why?
| | Protein Binding | 2 | 2002 | 2235 | 0.010 |
Why?
| | Reference Values | 1 | 2006 | 801 | 0.010 |
Why?
| | Young Adult | 1 | 2020 | 13378 | 0.010 |
Why?
| | Autoantigens | 1 | 2006 | 422 | 0.010 |
Why?
| | Knee Joint | 1 | 2006 | 407 | 0.010 |
Why?
| | Chromatography, Gel | 1 | 2002 | 130 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 336 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2002 | 394 | 0.010 |
Why?
| | Plasmids | 1 | 2002 | 359 | 0.010 |
Why?
| | Cytoskeleton | 1 | 2002 | 194 | 0.010 |
Why?
| | Titrimetry | 1 | 1999 | 12 | 0.010 |
Why?
| | Consensus Sequence | 1 | 1999 | 73 | 0.010 |
Why?
| | Static Electricity | 1 | 1999 | 117 | 0.010 |
Why?
| | Solvents | 1 | 1999 | 112 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 1999 | 225 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2002 | 399 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2011 | 7686 | 0.010 |
Why?
| | Temperature | 1 | 2002 | 660 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1355 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 1999 | 372 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 1649 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1999 | 557 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2049 | 0.010 |
Why?
| | Thermodynamics | 1 | 1999 | 423 | 0.010 |
Why?
| | Software | 1 | 2002 | 670 | 0.010 |
Why?
| | Aged | 1 | 2011 | 24186 | 0.010 |
Why?
| | Middle Aged | 1 | 2011 | 33811 | 0.000 |
Why?
|
|
Frank's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|